Based on our previous studies on dual blockade of complement and TLRs, i.e. the co-receptor CD14 used by both TLR4 and TLR2, to attenuate systemic inflammation21, we hypothesized that an upstream combined inhibition of complement component C5 and the CD14 molecule would attenuate the downstream BD-induced inflammatory response. This evidence concerns the gene CD14 and Behcet disease.